Crossmark

838 Combination MRx0518 and anti-PD-1 overcomes checkpoint inhibitor resistance via myeloid modulation

Crossref DOI link: https://doi.org/10.1136/jitc-2022-SITC2022.0838

Published Online: 2022-11-07

Published Print: 2022-11

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Li, June

Millerchip, Karen

Ramos, Carlos

Parra, Edwin

Solis, Luisa

Stevenson, Alex

Couturier, Aurelie

Fyvie, Gayle

Chisamore, Michael

Parikh, Rahul

Bernicker, Eric

Davar, Diwakar

Chaudhry, Arvind

Tannir, Nizar

Pant, Shubham

Haymaker, Cara
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct03637803 at ClinicalTrials.gov

Documents that mention this clinical trial

838 Combination MRx0518 and anti-PD-1 overcomes checkpoint inhibitor resistance via myeloid modulation
https://doi.org/10.1136/jitc-2022-sitc2022.0838

805 Safety and emerging evidence of immune modulation of the live biotherapeutic MRx0518 in the neoadjuvant setting for patients awaiting surgical removal of solid tumours
https://doi.org/10.1136/jitc-2020-sitc2020.0805

283 Safety and efficacy signals in the complete phase I study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients refractory to immune checkpoint inhibitors (ICIs)
https://doi.org/10.1136/jitc-2020-sitc2020.0283